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Factor IXL,,,,g&a& has a single  amino  acid  substitution 
a t  397 (Ile  to  Thr)  in  the  catalytic  domain  which  results 
in severe hemophilia B. Recent investigations have 
shown  that  the  substitution of threonine  for isoleucine 
a t  397 may  affect a part of the  macromolecular  sub- 
strate binding site. Because threonine  has a hydroxyl 
group  in  its  side  chain,  it is possible that  this  hydroxyl 
group makes new hydrogen bonds and disturbs the 
substrate  binding site. We used three techniques: mo- 
lecular biology, which  includes  site-directed  mutagen- 
esis  and  recombinant  protein  expression  in  tissue cul- 
ture;  computer-aided  kinetic  data  analysis;  and molec- 
ular modeling to  study  this  mutation  site. 
We have produced two  mutant  factor IX molecules 
that  have isoleucine 397 replaced  by  valine or  threo- 
nine. Factor IXwild type and  the  two  mutants  (factor IXv-1 
and  factor IXThr) were expressed  in  human  kidney  cells 
and purified  using a conformation-specific monoclonal 
antibody column. 
After the  activation by factor  XIa,  these  three mol- 
ecules  were  able  to bind  p-aminobenzamidine and in- 
crease  its fluorescence intensity  in a similar  manner. 
Factor IXV,l and  factor IXwild type had  indistinguishable 
activities  in  an  activated  partial  thromboplastin  time 
(aPTT) assay and  similar  kinetic  parameters  with  fac- 
tor X as a substrate.  Factor IXThr had  only 5% clotting 
activity compared with normal factor IX, a slightly 
lower K,,, and significantly  reduced kcat, using  factor X 
as a substrate. 
We developed energy-refined (AMBER v.3.1) com- 
puter models of the  three  factor IX molecules based on 
previous  work.  Three  factor IXa models (Ile, Val, or 
Thr  at 397) with a fragment of the  factor X activation 
site  were used to  predict  the  effect of the  mutation  at 
397 and  evaluate  the  significance of the  new  hydrogen 
bond  thought  to  form  between  the  side  chain  hydroxyl 
group of threonine 397 and the carbonyl oxygen of 
tryptophan 385. This  new  hydrogen bond  would  affect 
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the position of an  amide  proton of adjacent  glycine 386 
which has been proposed to make a hydrogen bond 
with a backbone  carbonyl  oxygen of the P3 residue of 
factor X. In addition  to  the  new  hydrogen bond, there 
is significant movement in  the  side  chain of tryptophan 
385 between  the  factor IXawila  typ,-factor X model and 
the  factor IXaTh,-factor X model that could interfere 
with  substrate binding. This movement could be caused 
by the  change  in  the molecular  volume, the  orientation 
of the side  chain at 397, and  the  new  hydrogen bond. 
Factor IX (Christmas factor) is the zymogen of a serine 
protease,  factor  IXa,  active  in  normal  hemostasis (1). Defec- 
tive  factor  IX  results  in  the bleeding  disorder  hemophilia B. 
Factor  IX  is  activated by XIa or VIIa-tissue  factor by cleavage 
a t  residues 145/146 and 180/181 (1, 2). Activated factor IX 
with its  cofactor,  factor VIIIa,  cleaves factor X to  Xa.  Factor 
IX  is  one of the  group of vitamin  K-dependent  clotting  factors 
which include factors  IX,  X,  VII,  and  prothrombin  (Mann et 
al., 1990). All of these  proteins include a light chain which 
consists of a Gla domain  containing y-carboxyglutamic  acid 
(Gla) residues and two epidermal growth factor-like  domains 
or two  kringle domains,  an  activation  peptide region, and a 
heavy chain  that  contains  the  protease  active  site.  The  serine 
protease domain contains the catalytic triad of histidine, 
aspartic acid, and  serine  and  shares  remarkable  amino acid 
sequence similarity  with  trypsin  and  chymotrypsin. 
The crystal structures of numerous families of proteins 
have revealed that evolutionarily related  proteins with similar 
primary sequences share a similar three-dimensional struc- 
ture (3, 4, 5 ) .  The  serine  proteases  and  their zymogens com- 
prise  such a  family and have become textbook models of this 
hypothesis (6). The  backbone  atoms of the  serine  proteases 
are  essentially  identical;  most of the sequence changes reside 
in surface residues. Thus, there is ample justification for 
modeling the  structure of the heavy chain of factor  IX from 
the crystallographic structure of trypsin and thrombin (7). 
Based on this assumption, we developed factor IX models 
which indicate  that residue 397 in factor  IX is equivalent  to 
residue 227 in trypsin according to  the  chymotrypsin  num- 
bering scheme. Residue 227 is located internally near the 
substrate  binding pocket. I t  was suggested that  the hydroxyl 
group  in the side chain of threonine,  the  mutated residue, is 
responsible for the loss of the  activity (8). To examine  this 
hypothesis, we chose to  substitute valine  for this residue and 
analyze  the effect on  catalytic activity.  Valine and  threonine 
have  similar molecular  volume, whereas valine and isoleucine 
have nonpolar side chains.  Therefore,  any difference in  activ- 
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ity between factor IXaTh, and factor 1Xav.l could be attributed 
to differences in the electrostatic  properties of the side chain. 
From this similarity of the side chains of valine and isoleucine 
and  the fact that valine is commonly found at this position in 
other serine proteases, we predicted that factor IXa with 
valine at 397 would  have catalytic activity similar to normal 
factor IXa. 
We used recombinant techniques to produce the factor 
IXval, factor IXThr, and factor IXwildtme and obtained sufficient 
material for characterization. Simultaneously we developed a 
computer program to analyze the kinetic parameters of the 
activation of factor X by the activated factor IXs. Computer 
models of the factor IXa heavy chain with the factor X 
activation site were used to predict the microenvironmental 
changes in the substrate binding site caused by the mutations. 
EXPERIMENTAL  PROCEDURES 
Materials 
The following oligonucleotides were used for the mutation from 
isoleucine to valine at 397,  5"GGCAAATATGGAGTATATAC- 
CAAG; for isoleucine to threonine at 397,  5"GGCAAATATGGAA- 
CATATACCAAG. T7 DNA polymerase (Sequenase), polynucleotide 
kinase, and T4 DNA ligase were obtained from either Bethesda 
Research Laboratory (BRL), New England Biolabs, or Boehringer 
Mannheim. "'1-Protein A, Na'2sI, and ["'SIdATP were purchased 
from Amersham Corp. Affi-Prep 10 was obtained from Bio-Rad, 
Iodobeads from Pierce Chemical Co., and Geneticin (G418) from 
GIBCO. Human plasma factor IX, human factor X, human factor 
Xa, human antithrombin 111, and human thrombin were purchased 
from Enzyme Research Lab (South Bend, IN). Human factor X 
preparation was dialyzed against TBS (150 mM NaCl, 20 mM Tris- 
CI (pH 7.2)) before performing kinetics experiments. Human factor 
XIa was purified as described (9). Spectrozyme FXa (methoxycar- 
bonyl-D-cyclohexylglycyl-glycylarginine-p-nitroanilide acetate) and 
human factor IX-deficient plasma were purchased from American 
Diagnostica or Sigma. Platelin  Plus Activator was purchased from 
General Diagnostics (Morris  Plains, NJ). 
Three monoclonal antibodies to human factor IX were used in this 
study: A-1, A-5, and A-7 (10). The amino acid sequences of human 
factor IX recognized by these antibodies are: A-1, residues 147-153 
(activation peptide); A-5, residues 180-310 (heavy chain) (11). A-7 is 
a Ca'+-dependent conformation-specific antibody that recognizes 
amino acids 1-42 (Gla domain of human factor IX); it fails to bind 
bovine factor IX.' All other reagents were of the highest purity 
commercially available. 
Methods 
Zn Vitro Mutagenesis and Construction of Expression Plasmids- 
Site-directed mutagenesis was effected as described by Kunkel (12). 
Each mutated cDNA  was sequenced by the dideoxy chain  termination 
method (13). Site-directed mutagenesis and DNA sequencing were 
performed using a phagemid pMA254 (14), and factor IX cDNA  was 
ligated into a expression vector pCMV4 at  the BamHI  site (15). 
Cell Culture and Transfection by the CaPO, Method-Human em- 
bryo kidney 293 cells were  grown in  a mixture of Dulbecco's modified 
Eagle's medium and F-12 medium (1:l) supplemented with 10% fetal 
calf serum (growth media). Transfection was performed using the 
calcium phosphate co-precipitation method (16).  Twenty pg  of 
pCMV4 factor IX DNA and 2 pg of pSV2-neo (17) were used to 
transfect cells grown in 100-mm dishes. Transient expression levels 
were measured by the  aPTT2 clotting assay and immunoradiometric 
assay. Two days after transfection, cells were passaged and grown 
with growth  medium containing 500 rg/ml G418 for selection. Two 
to three weeks later, the surviving foci were isolated with cloning 
cylinders into 12-well dishes. Each clone was  grown to confluency in 
the presence of 5 pg/ml vitamin K, and  the expression level of factor 
IX of each clone was measured by an immunoradiometric assay using 
antibodies A-7 and A-1. Clones expressing a high level of carboxylated 
' K. Smith, unpublished observation. 
The abbreviations used are: aPTT, activated partial thrombo- 
plastin time; SDS, sodium dodecyl sulfate; PAGE, polyacrylamide gel 
electrophoresis. 
factor IX were established as cell lines for further analysis. 
Each cell line was expanded into roller bottles for large scale 
production of recombinant factor IX. The cells were  grown to semi- 
confluence in the presence of 7% calf serum and  then  the amount of 
calf serum was reduced to 5%, and 5 pg/ml vitamin K was added as 
a supplement. The culture medium was collected twice weekly for 
several weeks until the cells started detaching from the surface of the 
bottles. 
Polyacrylamide Gel Electrophoresis-SDS-polyacrylamide gel  elec- 
trophoresis (SDS-PAGE) was performed as described (18). Following 
electrophoresis, the proteins were visualized by staining with Coo- 
massie Brilliant Blue R-250. 
Iodination of Protein-One-hundred pg of monoclonal antibody 
was labeled with N a Y  using Iodobeads according to  the manufac- 
turer's  instructions  (Pierce). The radiolabeled antibody was separated 
from free "'1 on a Sephadex G-25 column. 
Zmmunoradiometric  Assay-Three monoclonal antibodies (A-1, A- 
5, and A-7) were used in the assay as described (10). These assays 
show no cross reactivity with bovine factor IX in culture superna- 
tants.  A-l or A-5 was used at an  appropriate dilution (-50 pg/ml) in 
50 mM NaHC03  (pH 8.5) to coat the 96-well microtiter plate. Samples 
containing factor IX were diluted in TBS,  and 0.1% ovalbumin and 
subsequently added to  the wells. After incubation at 4 "C overnight, 
second antibodies A-7, labeled with lZ51, were added at  1 X lo5 cpm/ 
well.  A-7  was diluted in the presence of 5 mM CaC12 and 1 mM  MgClZ. 
Unbound radioactive antibodies were  removed after  a 4-h incubation, 
and  the radioactive content of each well  was measured. 
Purification of Recombinant Factor ZX-The culture medium con- 
taining 5% calf serum was filtered to remove  cell debris. The filtrate 
was applied to a column containing the conformation-specific mono- 
clonal antibody A-7  coupled to  an Affi-Prep 10 at 3-5 mg/ml. After 
washing the column with 20 mM Tris-CI (pH 7.2), 100 mM NaCI, 5 
mM CaCl,, 1 mM MgCl,, and  then washing with 20 mM Tris-CI (pH 
7.2), 1 M NaC1, 5 mM CaClZ, 1 mM MgCI,, factor IX was eluted with 
20 mM EDTA in TBS. A peak of eluted protein was detected by 
measuring the absorbance at 280 nm, and the eluted protein was 
concentrated with a Centricon 30 ultrafilter (Amicon). The concen- 
trated protein was dialyzed against TBS. The purity of the sample 
was checked using SDS-PAGE  under reducing conditions. 
Clotting Assay-One-stage aPTT assays were performed as de- 
scribed in the manufacturer's instructions (Organon Teknika). The 
ability of the proteins to correct the clotting time of factor IX- 
deficient plasma was calculated from a standard curve derived with 
pooled normal human plasma. 
Actiuation by Factor XZa-The activation of human factor IX by 
human factor XIa was accomplished in the presence of 5 mM CaCL 
at an enzyme to substrate  ratio of  1:lOO-400  (w:w). The concentration 
of factor IX was approximately 5 p ~ .  After incubation for 1 h at 
37 "C, activated factor IX was subjected to SDS-PAGE to verify the 
activation. 
Activation of factor IX by factor XIa was also examined by moni- 
toring the change in fluorescence of p-aminobenzamidine resulting 
from its binding to the active site of factor IXa (19). Reaction 
solutions  contained 250 nM factor IX, 150 pM p-aminobenzamidine, 
0.5% polyethylene glycol-8000, 5 mM CaCI, in TBS. The reactions 
were initiated by adding factor XIa  at  an enzyme to substrate ratio 
of  1:120 (w/w) to a microcuvette containing the reaction components. 
The change of fluorescence intensity a t  376 nm (excitation at 336 
nm) was monitored at room temperature with a Shimadzu RF-5000 
spectrofluorophotometer. 
Actiuation of Factor X by Recombinant Factor IXs-Activation of 
factor X by factor IXa was analyzed by monitoring the sequential 
hydrolysis of a chromogenic substrate (Spectrozyme FXa) with 5 mM 
CaCl, as  the only cofactor. For factor IXwild tvpe and factor 1Xv.1, the 
reactions contained 250 nM activated factor IX, various concentra- 
tions of human factor X,  and 0.2 mM Spectrozyme FXa in TBS with 
5 mM CaCI, and 0.5% polyethylene glycol-8000. In  the factor IXTW 
competitive experiment, the reaction mixture contained 500 nM ac- 
tivated factor IXwild type and 500 nM factor X. The concentration of 
activated factor I X T ~ ~  was 0.0, 1.0, or 2.0 pM. 
Computer-aided Data Analysis-The kinetic parameters for factor 
X activation were determined using a program developed in our 
laboratory which solves coupled differential equations using the 
Gear's backward step method and estimates the fit of the model to 
the experimental data using the Levenberg-Marquardt method (20). 
This program used the IMSL math/library version 1.0 subroutine 
DIVPAG (IMSL,  Texas) to solve the coupled differential equations. 
The nonlinear  least  squares implementation of the Levenberg-Mar- 
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quardt method was developed based on a published program (20). 
Because of the likelihood of the condition of stiffness, the parameters 
were transformed into logarithms prior to fitting. The program is 
able to analyze data from several reactions with different substrate 
or enzyme concentrations and simultaneously allow weighting of the 
data in a desirable manner. All calculations were performed using 64- 
bit precision. The program was written in Fortran 77 and run on  a 
Digital Equipment Corp. VAX  6420 and is available from the  authors 
upon request. 
The model  used to analyze the kinetic parameters was 
kl kl 
E + S , ~ E S 1 - E + P ,  
kz 
E, + S I  * Ems, + E, + P1 kq kc 
k, 
P, + s, s PIS, + PI + P, 
where E represents the first enzyme (factor IXwildtlpe  or factor IXV.,), 
E,  the second enzyme (factor IXThr), sl the first  substrate  (factor x ) ,  
P1 the first product (factor Xa), Sz  the second substrate (Spectrozyme 
FXa), and P, the second product (p-nitroanilide). 
The four coupled differential equations which  were  solved to esti- 
mate the absorbance of p-nitroanilide at  404 nm  were the following: 
d[ES,]/dt = kl X ([Et] - [ESl]) X ([Sl!t,l - [E&] 
- [Ems11 - IPl(t11) - kz X [Est] - k, X [ESl] 
d[E,Sl]/dt = k, X ([Ernct!l - [Ems,]) 
E,, Em(r,, S1(,, and are total (initial) concentrations of E, E,, S,, 
and SB, respectively. ABS represents the absorbance at 404 nm. PICt) 
represents total activated factor X in the system. Since in the se- 
quential reaction catalyzed by activated factor X,  the substrate con- 
centration (Spectrozyme FXa, 0.2 mM) was very much larger than 
that of the enzyme (factor Xa),  the Michaelis-Menten equation was 
applied to estimate the product of the sequential reaction. KA and 
k L  are  kinetic  parameters of Spectrozyme FXa hydrolysis by human 
factor Xa; KA is 3.5 X M,  and k:, is 2.7 X lo3 min". C is the emax 
ofp-nitroanilide released from Spectrozyme FXa; 1.3 X 10' M-'. 
In each iteration, estimated parameters are used to generated 
absorbance profiles using the Gear's backward step method, and by 
using the Leverberg-Marquardt method the parameters (k , -k6 )  are 
evaluated through fitting the generated absorbance profiles to the 
experimental data  and a new set of estimated  parameters are gener- 
ated for the next iteration. 
Molecular Modeling-All calculations were performed using the 
AMBER program ( 21) on a Cray Y-MP 8/432 or  a Convex '2-240 
computer system. Visualization was performed on a Silicon Graphic 
IRIS 3031 workstation using the Molecular Modeling System (MMS) 
software version 1.3  from University of California San Diego (22). 
The original model for factor IX was  developed from the structure 
of  bovine pancreatic  trypsin as described previously (8). The trypsin 
x-ray crystallographic waters were added to this model via least 
squares  fitting of the protein backbone atoms. All protein models and 
the fitted trypsin crystallographic waters were further solvated by 
immersion into  a rectangylar box  of TIP3P water molecules. Water 
molecules  less than 10.0 A from any solute atom were retained. The 
following procedures were used for the calculations; each system was 
energy minimized using 100 cycles of the steepest descent method 
followed  by the conjugate gradient minimization until  a convergence 
criterion of  0.1 kcal/mol-A root mean square deviation gradient was 
reached. Constant pressure with periodic boundary conditions, and a 
residue-based 8.0-A nonbond interaction cutoff were applied the 
nonbond interaction  list was updated every 50 steps, and a constant 
dielectric of  1.0  was employed. SHAKE was applied to all hydrogens, 
and the protein termini were treated as  the fully ionized species. 
The factor IXa model containing isoleucine at position 397 was 
changed to both valine (factor 1Xav.l) and threonine (factor IXaTh,). 
For the factor IXaTh, model, two side chain conformations were 
chosen as starting structures; in one of these conformations, the 
hydroxyl group of threonine was directed toward the carbonyl oxygen 
of tryptophan 385, whereas in the other comformation, the hydroxyl 
group of threonine was directed toward the side chain of serine 384. 
Each of these solvated models (factor IXaWild type, factor IXaVal, and 
the two conformations of factor IXaTh,) was energy-minimized using 
AMBER v3.1 (fully vectorized version of AMBER v3.0 by U. C .  
Singh, P. K. Weiner, J. W. Caldwell, and P. A. Kollman, University 
of California San Francisco, 1986). 
Molecular dynamics was performed on the factor IXawIld type model. 
The energy-minimized structure of factor IXaWild was exposed to 
50 ps of molecular dynamics using a time step of 0.001 ps at a 
constant temperature of  300 K and under a  constant pressure at 1.0 
atm. All other computational details were the same as for the previ- 
ously described energy minimization procedures. 
A factor IXa model interacting with the activation site of factor X 
was developed based on the crystallographic structure of the trypsin- 
bovine pancreatic trypsin inhibitor complex (Brookhaven Protein 
Data Bank, PDBlTPA).  The 7 residues 190-196 (Asn-Asn-Leu-Thr- 
Arg/Ile-Val) at  the activation site of factor X (23) were fitted to  the 
positions of the corresponding backbone atoms and any similar side 
chain atoms at  P5-P'2 of bovine pancreatic trypsin inhibitor. Sub- 
sequent solvation and energy minimization was performed using 
AMBER v3.1 as described previously, except that in this case water 
molecules more than 8.5 A from any solute atom were discarded. 
RESULTS 
Expression and Purification of Recombinant  Factor IXs- 
Human kidney  embryo 293 cells which were transfected with 
pCMV4 containing  factor  IX cDNA (pCMV4FIXwild type, 
~CMV~FIXV, , ,  or pCMV4FIXTh,) and pSV2neo were analyzed 
for transient expression 24 h after transfection. To avoid 
contamination of bovine factor IX in  the  aPTT clotting, the 
cells were washed  using  media  without  fetal calf serum twice 
and  then  incubated with  media containing 5 pg/ml vitamin K 
in  the absence of fetal calf serum for 24 h. The  amount of 
factor IX in  the  culture  supernatant was measured  using the 
aPTT clotting assay and  the radioimmunoassay. All super- 
natants contained about 50 ng/ml FIX antigen except the 
supernatant from mock-transfected cells. The supernatants 
f rom  ce l l s   t ransfec ted   wi th   pCMV4FIXwild  t y p e  a n d  
pCMV4FIXvaL decreased the  clotting time to  about 70 s from 
150 s. The  supernatant from cells with  pCMV4FIXTh, showed 
no  detectable  difference in  the  clotting assay  from the  super- 
natant from mock-transfected cells. 
After a few weeks selection  with antibiotic G418, surviving 
colonies were isolated into a 24-well dish and were grown to 
confluence. The  factor  IX expression level of each clone in 
the presence of 5 pg/ml vitamin K was measured by the 
radioimmunoassay. The clone which had  the highest  expres- 
sion level (several hundred ng/106 cells/24 h) from  each 
construct was expanded  into roller bottles. The  culture media 
collected under the conditions described under "Methods" 
contained  about 0.5-1.0 pg/ml carboxylated  factor  IX. Since 
protein  contaminants from serum in the media were low and 
the expression level of factor IX was relatively high, the factor 
IX secreted into  the media could be purified through a single 
pass over an A-7 monoclonal antibody column.  Purified re- 
combinant factor IXs were subjected to SDS-PAGE under 
reducing conditions  and were analyzed by staining with Coo- 
massie Brilliant Blue R-250 (Fig. l). The  recombinant factor 
IXs  migrated  as a single band  and  the mobility was equivalent 
to plasma factor IX. 
Clotting  Activity of Recombinant  Factor IXs-The clotting 
activity of purified recombinant factor IXs was compared 
with purified plasma factor IX in the aPTT assay using a 
standard curve  from a series of dilutions of normal plasma 
(Table I). The protein concentration of each sample was 
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FIG. 1. SDS-PAGE of factor IX and factor IXa. Purified 
recombinant factor IXs (1.0 pg/lane) were  subjected on SDS-PAGE. 
Lanes I and 6 shows the molecular weight marker  purchased  from 
Sigma. Lanes 2 and 7 show  purified plasma  factor IX. Lanes 3 and 8 
show recombinant  factor  IXWila ,>w Lanes 4 and 9 show recombinant 
factor IXvnl and lanes 5 and 10 show recombinant factor IXrh,. 
Samples on lanes 5-10 were incubated with factor XIa before the 
electrophoresis  as described under  “Methods.” 
TABLE I 
Specific  activities of recombinant  factor IXs  
Factor IX Protein concentration  activity’ 
Specific 
w l m l  
Purified  plasma factor  IX 82.7 81 s 100% 
Recombinant  factor IXIild 108.0 78 s 95% 
Recombinant factor IXv,I 105.0 78s  959; 
Recomhinant  factor IX’rhr 105.0 142 s 
1050 86 s 5% 
Protein concentrations were estimated from the absorbance a t  
280 nm,  and  the  samples were diluted to  the  concentrations in the 
table. 
A standard  curve of the  clotting  activity was obtained for a series 
of dilutions of human pooled plasma,  and  the specific activities  are 
shown as relative activities to that of the purified human plasma 
factor  IX. 
calculated based on the absorbance at 280 nm using an 
extinction coefficient of 1.33 ml/mg/cm and M, = 57,000 (25). 
The clotting  activity of recombinant  factor  IXwild  and 
factor  IXV,~ was  95% of purified plasma  factor IX. The clotting 
activity of factor IXThr was not  detectable a t  similar  concen- 
trations of the  other  factor  IX molecules. At a 10-fold higher 
concentration (1.05 pg/ml),  factor IXThr significantly  de- 
creased the clotting time of the deficient plasma, and its 
clotting activity was estimated to be approximately 5% of 
purified plasma factor IX. This result is consistent with a 
report  that  the patient’s plasma  had  approximately 2.6% of 
normal  factor  IX  activity  with  62% of the  normal heavy chain 
and light chain factor IX antigen level (26). This indicates 
that  the  patient’s  factor  IX  had 4.2% activity a t   the  normal 
antigen level. 
Activation of Recombinant Factor IXs by Factor XIa-The 
activation of recombinant  factor  IX by factor  XIa was de- 
scribed  under “Methods.”  Aliquots of the  activated  factor  IXs 
were  subjected to  SDS-PAGE (Fig. 1) under reducing condi- 
tions.  The heavy chain  and  the  light  chain of these recombi- 
nant  factor  IXas  migrated  with  the  same mobility as those 
detected from purified plasma factor IX. The light chains 
were stained a t  lower intensity  than  the heavy chains. 
The  activation of factor  IX by factor  XIa was also  moni- 
tored using p-aminobenzamidine which binds  to  the  active 
site  after  the  factor  XIa  activation. All recombinant factor 
IXs were able to bind p-aminobenzamidine and change its 
fluorescence intensity (Fig. 2). Although the  small volume of 
the fluorescence  microcuvette can  save  material,  initial mix- 
ing  is difficult. Since  it was shown  that  p-aminobenzamidine 
0 5 1 0  
Time(hour) 
FIG. 2. Activation of recombinant factor IX by factor XIa. 
The reaction solutions contained recombinant factor IX (250 nM), 
factor  XIa  and  p-aminobenzamidine (150 p ~ ) .  Details  are described 
under “Methods.” The volume of the reaction solution was 300 pl. 
Fluorescence of p-aminobenzamidine was monitored using as an 
excitation wavelength 336 nm  and  an emission wavelength 376 nm 
a t  room temperature. The reactions were started by adding factor 
XIa. 0, factor  IXIila ,y,w; 0, factor 1Xy.1; A, factor 1Xl.k. 
can be  used to follow the reaction  for extended periods (191, 
we slowed the  reaction by using  less factor XIa. Monitoring 
the fluorescent change  during  sample mixing is thus avoided. 
Due  to  the  diminished  factor  XIa  concentration, maximum 
fluorescence changes were achieved  only after several  hours. 
This  result  is  reasonable when compared  with previous reports 
which  used much  greater  factor  XIa  concentrations (19, 27). 
A model of the  factor  IXa-p-aminobenzamidine complex was 
developed based on  the x-ray structure of the  trypsin-benz- 
amidine complex. Based  on  the model, it  is predicted that  the 
mutations a t  residue 397 would not affect the  binding of p- 
aminobenzamidine since this small inhibitor only interacts 
with  the P1 binding  site which did not include residue 397 
(data  not  shown). 
Kinetic  Analysis of the Activation of Factor X by Recombi- 
nant Factor IXm-The experiments for the activation of 
factor X by the  recombinant  factor  IXas were performed, and 
the  data were analyzed using the program described under 
“Methods.” The  simulated  reaction curves and  the  data  points 
from the  experiments with factor IXawild t.w is shown  in Fig. 
3. Because of the low activity of factor IXaTh, and relatively 
high background from the  factor X preparation, we evaluated 
the  kinetic  parameters of this  mutant  through  the competitive 
effect of Factor IXarhr on factor IXawild lml~ activation of 
factor X. The  results  from  the  competition  experiments  are 
shown  in Fig. 4. During  the  analysis of kinetic parameters of 
factor IXaTh,, the  kinetic  parameters of normal  factor IXa,,.ild 
were fixed to the estimated values from the previous 
experiment.  The  results  are  presented in Table 11. 
Molecular Modeling Results-The factor IXa models which 
contain isoleucine,  valine, or  threonine a t  position 397 were 
developed with crystallographic waters from the  trypsin x-ray 
structure. The system contained more than 35,000 atoms 
including water molecules. The energy  minimization was per- 
formed as described under “Methods.” In the energy-mini- 
mized structures of the two different  starting conformations 
of factor IXl.hr, the hydroxyl  group of threonine 397 made  a 
hydrogen bond  to  the backbone carbonyl of typtophan 385 
regardless of the  initial  orientation of the side chain of thre- 
onine; however, there was no significant  movement observed 
in  the backbone atoms of the  substrate  binding  site (residues 
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FIG. 3. Activation of factor X by activated factor IXwild type. 
Recombinant factor IX was activated by factor XIa as described 
under “Methods.” The  total volume of the reaction solution was 250 
pl. The reaction solutions contained factor IXa (250 nM) and 5 mM 
CaCl, in TBS are described under “Methods.” The reactions were 
started by adding factor X at  the various concentration: 0, 0.5 p ~ ;  
0, 1.0 pM; X, 2.0 PM; H, 3.0 pM; A, 5.0 pM; 0, 10.0 pM. The symbols 
represent experimental data points, and the lines are generated 
absorbance profiles at the different concentrations of substrate using 
the kinetic analysis program described under “Methods.” 
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FIG. 4. Inhibition by activated factor I X T ~ ~  of the activation 
of factor X. Recombinant factor IXawild type and factor IXaTh, were 
generated by factor XIa. The  total volume of the reaction solution 
was 250 pl. The reaction solutions contained factor IXaWild type (500 
nM), various concentrations of factor IXaTh, (0, 0 PM; 0, 1.0 p ~ ;  X, 
2.0 p ~ )  and factor X (500 nM). The details are described under 
“Methods.” The reactions were started by adding factor X. The 
symbols represent experimental data points, and  the lines are gener- 
ated absorbance profiles at  the different factor IXaTh, concentrations 
using the kinetic analysis program described under “Methods.” 
TABLE I1 
Kinetic Darameters of recombinant factor ZXas 
K ,  (I kc.,’ k c a t l K m  
~~~~ ~~~ ~ 
M min“ m i d  M” 
Factor IXuildtw 4.0 X 8.2 X lo-‘ 2.1 X 10’ 
Factor IXvaI 10.6 X 2.3 X 2.2 X 10’ 
Factor &hrb 1.8 x 1O“j  1.6 x lo-” 8.8 
The kinetic parameters were estimated using a program described 
* The kinetic parameters of factor I X T ~ ~  were determined  through 
under “Methods.” 
competition experiments. 
385-386) in  the energy-minimized structures. 
The molecular dynamics  calculation of factor  IXawildtme was 
performed to  simulate molecular motions of side chains of 
surface residues. After 30 ps, pseudo-equilibration was 
achieved; backbone atom {isplacements did not deviate by 
more than 0.1 A from  a 1.7 A root  mean  square deviation  with 
respect to  the  initial energy-minimized structure. An average 
structure from 30 to 50 ps was determined  and  the position 
of the  amide  proton of glycine 386 was compared  with this 
average structure.  The average fluctuation in  the  Totion of 
this amide proton  during  this  time period was 0.56 A. 
To  further characterize this model, we added the simulated 
factor  X activation  site  as described under “Methods.” The 
number of the atoms in this system was reduced aqproxi- 
mately to 26,000 because  water molecules less than 8.5 A away 
from any  solute  atoms were retained.  After the energy min- 
imization, three  structures were overlapped by fitting back- 
bone atoms  and  any  same side chain  atoms of the residues 
384-386 and 396-397 of factor IXa, and arginine at  P1 of 
factor X via least  squares  fitting (Fig. 5A). The  results suggest 
that  the  mutation from  isoleucine to  threonine  has two effects 
on  the  substrate  binding  at 385-386. One mutational effect is 
the  formation of a new hydrogen bond between the hydroxyl 
group of threonine 397 and  the backbone  carbonyl of trypto- 
phan 385. The  other  structural effect due  to  the 397 mutation 
was caused by a reorientation of the side chain of tryptophan 
385 which could increase steric repulsion between the sub- 
strate binding site and the substrate (P3). The improper 
torsion angle that defines the  orientation of the side chain 
ring of tryptophan relative to  its backbone  (CE3-CG-CA-C in 
tryptophan) in the factor IXaTh,-factor X model is 22.5”, 
whereas that  in  the  factor IXa,ild  t,,-factor X model is 13.3” 
and  that  in  the  factor  IXaval-factor X model 15.5” (Fig. 5B). 
In  the overlapped models, the carbonyl carbon of leucine (P3) 
of factor  X in  the  factor  IXaThr-factor X model, that makes 9 
hydrogen bond with glycine 386, moved approximately 0.3 A 
from that  in  the  factor IXaWild tme-factor X model, the side 
chain of leucine (P3) that contacts wi$h the side chain of 
tryptophan moved approximately 1.0 A between these two 
models. 
DISCUSSION 
The purpose of our  study was to  evaluate  the effects of the 
factor IXLong Beech (28) mutation which causes moderately 
severe  hemophilia B. This  same  mutation  has been reported 
as  factor I X V ~ ~ ~ ~ ~ ~ ~ ~  (26),  factor IXt,, Angeles (29),  and recently 
this mutation was found as a common cause of moderate/ 
mild hemophilia B in western Europe (30). Previous  studies 
(8) showed this factor IXa mutant to have a significantly 
reduced kcat and slightly  higher K,,, than normal  toward  factor 
X. Its activity was indistinguishable  from normal factor IXa 
toward a small  substrate  (29). 
Our recombinant factor IX molecules, expressed in  human 
kidney cells, had molecular weights indistinguishable from 
purifiedplasma  factor  IX on SDS-PAGE.  The specific activity 
of factor IXwild type and factor IXV,~ were about 95% of plasma 
factor  IX. The specific clotting activity in  the aPTT assay of 
factor IXThr, 5% of normal, was consistent with that of a 
patient’s  factor  IX  (26). 
Since we expected that  the  mutation  at position 397 would 
affect  either  the  substrate  binding  site or the active  site, we 
performed the  experiments  in  the absence of the cofactors, 
factor VIIIa and phospholipid, to make the  results easier to 
interpret  and less ambiguous. However, the activity of factor 
IXaTh,  in  the absence of the cofactors was too low to measure 
the kinetic parameters directly. Since a previous study (8) 
indicated that the mutation would affect kcat to a greater 
extent than K,, we determined the K,,, of factor  IXaTh, 
through its competitive  effects  on the activity of factor IXawild 
type. In  this  experiment,  factor IXaTh, is expected to compete 
with factor IXa,ild tM)e for the  substrate.  Thus,  to maximize 
our chances of measuring an effect, the reaction was per- 
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/ TRP 385 ~ I TRP 385 
f a c t o r  IXa  w i l d  t y p e  factor  IXa va l  f a c t o r  IXa thr 
FIG. 5. The  energy-minimized  factor  IXa-factor X activation  site complex model. A, stereo drawings 
of the overlapped factor IXa-factor  X complex  models. The model includes residues 385-386 (Trp-Gly)  and 397 
(Ile, Val, or Thr) of factor IXa  and  the  P3-Pl activation site of factor X. Factor X  appears in the left  side of the 
figure. The solid thick lines represent factor IXaWild  tme-factor  X model. The thinner solid lines represent factor 
IXav,l-factor X model, and  the thick dashed lines represent factor IXaTh,-factor X model. The thin dotted line 
represents the new hydrogen bond formed between the side chain of threonine 397 and the backbone carbonyl 
oxygen of tryptophan 385  which is 2.75 A in length. B,  the  P3 substrate binding site of each factor IXa-factor X 
models. The figures include residues 385-386 (Trp-Gly) and 397 (Ile, Val, or Thr) of factor IXa. The torsion angles 
of the side chain of tryptophan are measured between CE-CG-CA-C (CE and CG in the side chain, CA and C in 
the backbone of tryptophan).  The torsion angles of the peptide bond plane w: CA(385)-C(385)-N(386)-CA(386) are
also shown. 
formed with  a  relatively low concentration of factor X. Be- 
cause  these  conditions  do  not  satisfy  the  assumptions neces- 
sary  to employ the  Michaelis-Menten  style  kinetic  analysis, 
we developed a computer program to analyze the  data  and 
determine  the  kinetic  parameters.  Our  program was developed 
based  on  the  same  technique  as previous work by other groups 
(31, 32). This program generates concentration profiles by 
solving  coupled differential  equations. The equations are 
based  on a  user-supplied model and  are solved  by the Gear's 
backward step  method (20). Parameter  estimates  are  obtained 
by fitting  the  results  from  the  simulation  to  the  experimental 
data using the Levenberg-Marquardt method (20). A major 
advantage of this  program  is  that  it  can easily be modified to 
accommodate experimental conditions. This  results  in  saving 
both time and materials. On the other hand, one must be 
careful  to properly set  the  experimental  conditions so that a 
unique meaningful solution is obtained. 
First, we determined the kinetic parameters of factor 
IXaWild tme: K,,, = 4.0 p M  and kcat = 8.2 X min" (Table 
11). The K,  value is lower than  that  reported by Geddes (8) 
which  was determined  in  the  presence of poly-L-lysine ( K ,  = 
10 p ~ ) .  It  agrees well with  the K,,, reported by Mertens  and 
Bertina (33) in  the  presence of Ca2+ ( K ,  = 4.6 pM). We  tried 
experiments  with poly-L-lysine as a  cofactor  according to  the 
method described  previously (8), and we observed that Ca2+ 
and  NaC  at  the  concentrations used in  the  reaction signifi- 
cantly inhibited the enhancement by poly-L-lysine. I t  was 
reported previously that  various  ions including Ca'+ and Na' 
inhibit  the  enhancement by poly-L-lysine on  the  activity of 
factor  Xa (34). 
We expected that factor IXaval would have comparable 
activity  to  normal  factor  IXa because of the  nonpolar side 
chain of valine being  similar to  that  of isoleucine and  the high 
frequency of valine at this  position  in  the  other  serine  pro- 
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teases. The  results showed that  factor  IXavar  had a  higher K,, 
10.6 p ~ ,  and higher k,,,, 2.3 X min" (Table 11), which, 
overall, makes  factor  IXaval a  slightly  more  efficient  enzyme 
than  normal  factor  IXa with  isoleucine at position 397. Sub- 
sequent  to  these  experiments, sequences of factor  IX from  six 
different species were published  (35) and,  interestingly, valine 
was  found at  this position in  rabbit  factor IX. 
Based on  the  kinetic  parameters previously determined  (8), 
we observed more inhibitory  activity  than we expected in  the 
competition experiment between factor IXawild and factor 
IXagrh,. The K ,  and kcat of factor IXaTh, were 1.8 pM and 1.6 
x min", respectively (Table 11). Overall, the  catalytic 
efficiency of factor IXaTh,  is 24 times lower than normal.  Even 
though the kinetic parameters of our recombinant factor 
IXaTh,  are different  from the reported kinetic  parameters of 
factor  IXVnncouver; K,,, 34 /IM and 8-fold  less catalytic  activity 
than  that of normal (8), the  catalytic efficiencies were similar. 
This 24-fold difference in  the  catalytic efficiencies between 
factor IXawild and factor IXaTh, is remarkably consistent 
with the difference in  the aPTT clotting activities between 
normal plasma and patient's plasma posessing only 5% of 
normal activity. This suggests that  the loss of the procoagu- 
lant activity of the  mutant  factor  IX  relates  to  details of the 
factor  IXa-factor X complex and  not  to  the  activation by its 
activator(s) or its cofactor  binding. 
The isoleucine at position 397 in factor IXa  is  predicted  to 
be  a  buried residue based  on the molecular modeling developed 
from the  trypsin  x-ray  structure.  This residue is located close 
to  the  substrate binding pocket  but  makes no direct  contri- 
bution to substrate binding. The model predicts that this 
residue interacts with the highly conserved substrate  binding 
site (Ser-Trp-Gly a t  residues 384-386) (36). The structural 
importance of this region to  protease activity has been exten- 
sively studied  in  trypsin,  chymotrypsin,  and subtilisin. Studies 
with trypsin (37) demonstrated  the  important  contribution of 
Gly216 and GlyiZ6 to substrate binding. These residues are 
equivalent  to residues Gly386 and Gly"' in  factor  IX,  both of 
which  make  direct contact with  isoleucine 397. In  their  study, 
the  mutation from glycine 216 to  alanine affected K, more 
than k,,,, and  the  mutation from glycine 226 to  alanine  af- 
fected kcat more than K,. More  interestingly, an enzyme  with 
both  mutations recovered the  ability  to  bind  substrates when 
compared  with the enzymes containing only a single mutation. 
This indicates the complexity of the  interactions  in  this region 
on  the molecular level. 
Geddes et al. (8) suggested that a new hydrogen bond 
between threonine 397 and  tryptophan 385 would cause  a 20" 
shift  in  the  peptide bond plane of tryptophan 385 and glycine 
386 which would result  in a 20" shift  in  the angle of a  hydrogen 
bond between a amide  group of glycine 386 and leucine (P3) 
of factor X based on a static model of factor  IXa heavy chain. 
They proposed that this change accounts for the mutant 
enzyme's  decrease in  catalytic efficiency. Calculations  based 
on  electrostatic bond  energies estimate  that a  deviation of 20" 
in  the angle from 0" reduces the binding  energy of a hydrogen 
bond by approximately 10% (38). The binding energy of a 
linear hydrogen bond is  approximately 1-3 kcalhond;  there- 
fore, this  shift in the angle of the hydrogen bond would change 
the  activation energy by approximately 0.1-0.3 kcal/mol. The 
difference in the  activation energies of different enzymes can 
be  experimentaly estimated from the difference in their  cat- 
alytic efficiencies using the following equation: AAG = 
- ~ ~ n ( ( k ~ ~ l / K , ) / ( k ~ ~ ~ / K ~ ) )  (39).  Application of this equation 
indicates there is approximately 2 kcal/mol  difference in the 
activation energies of factor IXawild tme and  factor IXaTh,. The 
shift  in  the hydrogen bond,  itself, does not seem adequate  to 
explain the decrease of catalytic efficiency of factor IXaTh,. 
Preliminary  results from a 50-ps molecular dynamics simu- 
latiqn  indicate  that  there  are large  movements  (approximately 
0.6 A) in  the surface  residues containing  the  factor X binding 
site of the heavy chain of factor IXawild  thus,  the 20" 
difference in the angle of an amide  bond  (approximately 0.3- 
A movement in  the position of its amide proton) observed in 
a static model could be in a range of the  internal motions. 
Although it is difficult to  estimate  the effect of a mutation 
simply from a static model, it is of questionable value to 
perform expensive calculations without structural informa- 
tion such as crystallographic data (40).  Therefore, we decided 
to use the  factor  IXa heavy chain  and  the factor  X activation 
site sequences (7 residues) to build a partial factor IXa-factor 
X complex model and  to calculate an energy-minimized struc- 
ture of each complex model with isoleucine, valine, or threo- 
nine at  397 to predict the  structural changes  induced by each 
mutation. The factor IXa-factor X complex model is more 
useful than  factor  IXa alone, because the  orientation of the 
surface  residues in  the  binding  site  is affected by the presence 
of the  substrate. Since we demonstrated  that factor IXav,I has 
normal catalytic activity, we can use the models of factor 
IXawild and factor IXavsl as standards to predict the effect 
of the changes occuring in  the model of factor IXaTh, with 
respect to  the activity. 
The energy-minimized structures of factor IXaTh,-factor  X 
complex model affirmed that  the new hydrogen bond would 
exist between the hydroxyl group of threonine 397 and  the 
backbone carbonyl oxygen of tryptophan 385 in the facto; 
IXaTh,-factor X complex; however, it caused only a 0.15-A 
shift  in  the position of the  amide  proton of glycine next  to 
tryptophan 385, which would cause- a few degree shift  in  the 
angle of a hydrogen bond  with the backbone  carbonyl oxygen 
of leucine in  factor X. However, this  shift may have greater 
effects further along the  peptide  chain on either side of this 
leucine. Comparison of three energy-minimized factor IXa- 
factor X complex structures suggests that  in  addition  to  the 
new hydrogen bond between threonine 397 and  tryptophan 
385 there are differences in steric interactions between the 
factor IXawild,,, model and  factor IXaTh, model (Fig. 5 ) .  This 
change in the steric interaction causes reorientation of the 
side chain of tryptophan 385. The difference in the  orientation 
of the side chain of tryptophan 385 (9") was greater than  the 
difference in  the  torsion angle (a) of the peptide bond plane 
between tryptophan 385 and glycine 386 (1") in  our models 
(Fig. 5B). The change in  the  steric  interaction of tryptophan 
385 and residue 397 is likely caused by the differences in  the 
molecular volume and  the charge  density of the side chains 
at  397 and  their  orientations.  The  resulting new orientation 
of the side chain of tryptophan 385 changes the hydrophobic 
interaction with the side chain of lpcine (P3) of factor X 
which has moved approximately 1.0 A from that  in  the factor 
IXawild  ,,,-factor X model. In the hirudin-thrombin x-ray 
structure,  the  tryptophan  in  thrombin  at  the  same position as 
385 in factor IX  is  part of a  large  hydrophobic  surface area 
which interacts with the inhibitor (5). I t  is likely that the 
large  hydrophobic  side chain of tryptophan of factor IXa also 
participates in nonpolar contacts with substrate which are 
required for  correct  alignment of the  substrate in the active 
site. These two structural effects, the new hydrogen  bond and 
the  altered hydrophobic interaction, whereas  only  marginally 
affecting the affinity of the enzyme  for its  substrate may work 
synergistically to  disorient  the  substrate relative to the active 
site  serine  thereby significantly  affecting kc,, (Fig. 5A). Over- 
all, our models indicate  that  the loss of the activity of factor 
IXaTh, is due to  the confornational  change at  tryptophan 385 
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caused by the new hydrogen bond and  altered  steric  interac- 
tions with threonine 397. Exprimental  results together with 
molecular modeling results  support  a premise previously dis- 
cussed (8) that  the  structural changes are small and  a mac- 
roscopic constant of binding such  as K,,, should be relatively 
unaffected, whereas kc,, that is highly dependent on precise 
structural  orientation is significantly affected. While the con- 
clution fits our results, we cannot eliminate the possiblity 
that effects of the mutation on other  parts of the binding site 
or  the binding pocket, that could not be predicted from our 
model, contribute to the mutant’s decreased catalytic effi- 
ciency. 
These studies address the effects of the factor IX mutations 
on a molecular  level by combining site-specific mutagenesis, 
computer-assisted data analysis, and molecular modeling. Al- 
though our results may help in elucidating the relationship 
between protein structure  and  function,  further developments 
in computer-aided kinetic analysis and  structural information 
are needed to fully explain the effects of the mutations. 
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